...
机译:CD19靶向CAR-T治疗,然后是HAPLoidentical HSCT用于难治性/复发急性白血病:优异的治疗效果
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang;
Innovative Cellular Therapeutics Co. Ltd;
Innovative Cellular Therapeutics Co. Ltd;
The First Affiliated Hospital School of Medicine Zhejiang University;
机译:CD19靶向CAR-T治疗,然后是HAPLoidentical HSCT用于难治性/复发急性白血病:优异的治疗效果
机译:低剂量CD19靶向嵌合抗原受体T(CAR-T)细胞免疫疗法在47例难治性B细胞急性淋巴细胞白血病(B-ALL)复发患者中的安全性和有效性
机译:移植前的MRD消极性预测汽车-T治疗的有利结果,然后是对复发/难治急性淋巴细胞白血病的HAPLoIdentical HSCT:多中心回顾性研究
机译:砷救生优于化疗和骨髓移植复发急性突出细胞细胞白血病:来自香港的十年经验
机译:复发性急性淋巴细胞白血病中NT5C2突变的机制和治疗靶点
机译:一项多中心回顾性研究表明移植前MRD阴性可预测CAR-T治疗后再行单倍体HSCT治疗复发/难治性急性淋巴细胞白血病的良好疗效
机译:靶向CD19和CD22的双特异性CAR-T细胞用于复发或难治性B细胞急性淋巴细胞白血病的成人治疗